Andere Sprachen Abliva AB

Aktien

A0X93Z

SE0002575340

ABLI

Verzögert Nasdaq Stockholm Andere Börsenplätze 12:42:40 02.05.2024			% 5 Tage	% 1. Jan.
0,172 ^SEK	0,00 %		+1,78 %	-29,94 %

23.02.	Abliva AB (publ) meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI
2023	Abliva AB erreicht das Ziel der Patientenrekrutierung für Welle 1 der FALCON-Studie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Amended number of shares and votes in Abliva AB (publ)	30.04.
Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue	25.04.
Abliva AB Publishes 2023 Annual Report	24.04.
Notice of Annual General Meeting of Abliva AB (publ)	22.04.
Abliva publishes rights issue outcome	19.04.
BioStock: Abliva's mission to become mitochondrial medicine powerhouse	08.04.
Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares	27.03.
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)	26.03.
BioStock: Abliva's CEO comments on the proposed capital raise	29.02.
Abliva AB Year-End Report January – December 2023	23.02.
Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23.02.
Notice of Extraordinary General Meeting of Abliva AB (publ)	22.02.
The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study	22.02.
BioStock: Abliva reaches enrollment goal	21.12.
Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	20.12.
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	20.12.
BioStock: Abliva's CEO: "Orphan drug designation is great validation"	15.12.
EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps	14.12.
Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354	14.12.
Abliva AB Interim Report January – September 2023	17.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Abliva AB

Aktien

A0X93Z

SE0002575340

ABLI

Andere Sprachen

Filter